Navigation Links
Riquent in Medical News

BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent

NOVATO, Calif. and SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) and La Jolla Pharmaceutical Company (Nasdaq: LJPC ) announced today that they have entered into an agreement to develop and commercialize Riquent(R), La Jolla's investigational drug ...

BioMarin Announces Second Quarter 2009 Financial Results

...8 exclude (1) stock compensation expense $34 million for 2009 and $25.3 million for 2008; (2) upfront license fees of $8.8 million associated with the riquent transaction million in 2009 and $1.4 million associated with the Summit transaction in 2008; (3) impairment charges of $5.9 million in 2009 and $4.1 m...
Riquent in Medical Technology

La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial

Data Support Ability of Higher Doses to Further Reduce Antibodies to Double-Stranded DNA SAN DIEGO, March 08, 2007 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company today announced positive interim antibody results from its ongoing double-blind, placebo-controlled randomized Phase 3 trial ...

La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent Lupus Phase 3 Trial

SAN DIEGO, March 20, 2007 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company today announced updated interim antibody reduction data for the Phase 3 trial of Riquent(R) (abetimus sodium), its drug candidate for systemic lupus erythematosus ("lupus" or "SLE"). The updated analyses reinforce ...
Riquent in Biological Technology

Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile

NOVATO, Calif., Feb. 12 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that in the first interim efficacy analysis (IEA) for the Riquent(R) Phase 3 ASPEN trial, the Independent Data Monitoring Board (DMB) determined that the continuation of the trial i...

BioMarin Announces First Quarter 2009 Financial Results

...arter of 2008; (2) upfront license fees of $8.8 million associated with the riquent transaction classified as research and development expense in the first qua...lion for 2008; (2) upfront license fees of $8.8 million associated with the riquent transaction million in 2009 and $1.4 million associated with the Summit tra...

BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results

...e* $110 to $120 Costs Associated with riquent Deal** Up to $15 Interest Income ...d development expenses associated with the riquent deal ** Represents upfront costs associated with the riquent deal to be allocated between research and ...
Other Tags
(Date:9/23/2014)... TUESDAY, Sept. 23, 2014 (HealthDay News) -- A test used ... geographic regions where certain lung infections are more common, a ... lung cancer is through the use of what,s known as ... imaging called FDG-PET is used, according to the study authors. ... do parts of the lungs that don,t have ...
(Date:9/23/2014)... Avid collector Andrew Hawley, from Vintage Rock Posters, ... Seattle concert posters. The Doors were a smash hit after ... The Seattle Eagles Auditorium concert was held on July 23. ... Eagles Auditorium in November the same year. The artist that ... in three colors. The poster is a split fountain silkscreen ...
(Date:9/23/2014)... What: Rutgers Presbyterian Church, a ... that embodies the inclusion and diversity of New ... the Ecological Crisis, a public lecture led by ... of Old Testament at Louisville Presbyterian Seminary. Tull ... lends insight into current ecological problems, including energy ...
(Date:9/23/2014)... A recent Oregon survey about an exercise DVD ... daily routine of elementary school students found it had ... teachers, and offered clear advantages for overly sedentary educational ... and produced by the Healthy Youth Program of the ... available nationally. , Brain Breaks leads children in 5-7 ...
(Date:9/23/2014)... OAK BROOK, Ill. (September 23, 2014) Both ... malignancy with screening computed tomography (CT) colonography greatly ... invasive follow-up tests precipitated by false-positive diagnoses, according ... issue of the journal Radiology . , ... target a specific organ. However, when screening for ...
Breaking Medicine News(10 mins):Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 3Health News:Patients accept false-positives to achieve diagnostic sensitivity 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 3
(Date:9/23/2014)... majority of drugs used to treat asthma today are the ... are urgently needed to treat this chronic respiratory disease, which ... to wheeze, cough, and find it difficult at best to ... is tough: asthma is a patient-specific disease, so what works ... animal models traditionally used to test new drug candidates often ...
(Date:9/23/2014)... , 23 de septiembre de 2014 ... del Sistema 1290 Infinity II LC, el ... Infinity en su portafolio de cromatografía líquida. ... y directores de laboratorio que alcancen nuevos ... facilidad de uso y capacidad de integración ...
(Date:9/23/2014)... Most organisms, including humans, have parasitic DNA fragments called ... genetic instructions in the process. And that phenomenon can ... at the University of Rochester now report that the ... age when a multi-function protein stops keeping them in ... , In a study published today in Nature ...
Breaking Biology News(10 mins):Airway muscle-on-a-chip mimics asthma 2Airway muscle-on-a-chip mimics asthma 3Agilent Technologies anuncia el lanzamiento del Sistema 1290 Infinity II LC 2Agilent Technologies anuncia el lanzamiento del Sistema 1290 Infinity II LC 3A multi-function protein is key to stopping genomic parasites from 'jumping' 2
Other Contents